3347 Stock Overview
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hangzhou Tigermed Consulting Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.45 |
| 52 Week High | CN¥69.50 |
| 52 Week Low | CN¥22.10 |
| Beta | 0.71 |
| 1 Month Change | 17.18% |
| 3 Month Change | 45.67% |
| 1 Year Change | -47.56% |
| 3 Year Change | -75.79% |
| 5 Year Change | n/a |
| Change since IPO | -72.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3347 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | 2.5% | 4.2% | 2.2% |
| 1Y | -47.6% | -64.9% | -7.9% |
Return vs Industry: 3347 exceeded the Hong Kong Life Sciences industry which returned -63% over the past year.
Return vs Market: 3347 underperformed the Hong Kong Market which returned -8.1% over the past year.
Price Volatility
| 3347 volatility | |
|---|---|
| 3347 Average Weekly Movement | 10.7% |
| Life Sciences Industry Average Movement | 10.8% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 3347's share price has been volatile over the past 3 months.
Volatility Over Time: 3347's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9,701 | Xiaochun Cao | www.tigermedgrp.com |
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary
| 3347 fundamental statistics | |
|---|---|
| Market cap | HK$51.59b |
| Earnings (TTM) | HK$1.83b |
| Revenue (TTM) | HK$7.82b |
30.2x
P/E Ratio7.1x
P/S RatioIs 3347 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3347 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.24b |
| Cost of Revenue | CN¥4.48b |
| Gross Profit | CN¥2.76b |
| Other Expenses | CN¥1.07b |
| Earnings | CN¥1.69b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.96 |
| Gross Margin | 38.10% |
| Net Profit Margin | 23.36% |
| Debt/Equity Ratio | 13.2% |
How did 3347 perform over the long term?
See historical performance and comparison